Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Adjuvant Treatment With Serplulimab，Trastuzumab and SOX in the of HER-2 Positive Gastric/Gastroesophageal Junction Carcinoma (GC/GEJC)

NCT06439550 is registered in ClinicalTrials.gov with The First Affiliated Hospital of Zhengzhou University as lead sponsor.

NCT NCT06439550
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06439550 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Adjuvant Treatment With Serplulimab，Trastuzumab and SOX in the of HER-2 Positive Gastric/Gastroesophageal Junction Carcinoma (GC/GEJC)
Lead sponsor
The First Affiliated Hospital of Zhengzhou University
Phase
Phase 2
Overall status
Not yet recruiting
Start date
July 15, 2024
Completion date
December 31, 2026
Enrollment
42 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

her2-positive gastric cancer